Navigation Links
Kidney disease worsens in a fourth of African-Americans despite therapy for hypertension
Date:5/5/2008

The best available treatment for chronic kidney disease from high blood pressure did not keep the disease from substantially worsening in about a fourth of African-Americans studied, according to long-term results of a National Institutes of Health study published April 28, 2008, in the Archives of Internal Medicine.

The largest and longest study of chronic kidney disease in African-Americans the African American Study of Kidney Disease and Hypertension (AASK) found that the disease substantially worsened in about one-fourth of participants, even with very good blood pressure control and use of kidney-protecting medications, currently the best available treatment. This subgroup of patients either lost half their kidney function or reached kidney failure, also known as end-stage renal disease.

"Despite these sobering results, blood pressure control is still vital in kidney disease and in many other diseases," said NIH Director Elias A. Zerhouni, M.D. "But this research clearly signals the importance of preventing kidney disease, better understanding causes and finding better ways to manage it in the 26 million Americans who already have it."

Good news also emerged from the study. About one-third of participants experienced a slow decline in kidney function, about what is generally observed with aging. "The factors that may be responsible for such a small loss of kidney function need to be studied," said Lawrence Y. Agodoa, M.D., senior author of the study and director of kidney failure research at NIHs National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which funded the study.

The AASK Cohort Study observed about 750 African-Americans on recommended therapy for chronic kidney disease from 2002 to 2007. Study participants were initially recruited beginning in 1995 for the AASK Clinical Trial www.nih.gov/news/pr/nov2002/niddk-25.htm, which concluded in 2001 that an ACE inhibitor medication protected the kidneys better than two other classes of blood pressure drugs. During the Cohort Study, nearly 9 out of 10 participants were taking an ACE inhibitor or an angiotensin receptor blocking drug, and average blood pressure was 133/78 mmHg, close to national guidelines for high blood pressure in people with chronic kidney disease.

Uncontrolled high blood pressure, an increase in the number of people with diabetes, and the aging of the U.S. population means more people than ever are getting and living with kidney problems. About 13 percent of the U.S. population, up from 10 percent in 1994, now have chronic kidney disease. And in 2005, more than 485,000 people were on chronic dialysis or had a kidney transplant for kidney failure, costing Medicare, private insurers and patients $32 billion.


'/>"/>

Contact: Mary Harris
niddkmedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Related medicine news :

1. Major League Baseball Hall of Famer Don Sutton Helps Kidney Cancer Patients Stay In The Game(TM)
2. 3 Women Suffer Kidney Failure After Derriere Injections
3. Bioartificial Kidney Cuts Death Risk, Improves Outcomes
4. Kidney Care Community Applauds National Taxpayers Unions Endorsement of Medicare Reforms to Extend Patient Private Health Insurance Coverage; Calls Proposal Common Sense Coverage Reform
5. Cutting Phosphate May Protect Kidney Patients From Heart Trouble
6. Muscle Mass May Not Explain High Creatinine in Black Kidney Patients
7. Readily available treatment could help prevent heart disease in kidney patients
8. Study Points to New Treatments for Polycystic Kidney Disease
9. Raloxifene Safe for Women With Decreased Kidney Function
10. Kidney cancer deaths show overall decrease in Europe
11. Diplomat Specialty Pharmacy Hires National Accounts Director To Expand Kidney Disease Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , ... April 28, 2016 , ... Head Over Heels ... 9 Western Championships. The competition will be held at the University of Montana on ... gymnasts west of the Mississippi River. , In order to qualify, Varize needed to ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... open availability of a new CDISC standard, Clinical Trial Registry (CTR) XML. ... This innovative standard will make it possible to build applications that generate ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online ... cosmetictown.com . The forum section was recently revamped and upgraded to allow even more ... in use across the country. , According to the senior editor of Cosmetic Town, ...
(Date:4/28/2016)... ... 2016 , ... Greener Hydroponics is now offering a large selection of Smart ... organic farmers and nurseries according to Sales Manager Joe Steele who says, “Now is ... is to offer wholesale level pricing and ultra-fast shipping for growers of any size.” ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine ... the emerging field of biomechatronics, technology that marries human physiology with electromechanics. He continues ... He is also the Founder of BionX , a leader in the field ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
(Date:4/27/2016)... 2016 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends, and ... global skincare devices market was valued at US$ 7,255.8 ... a CAGR of 10.1% from 2015 to 2023 to ... the full Skincare Devices Market (Treatment Device - LED Therapy ...
Breaking Medicine Technology: